Search for: "Pharmaceutical Manufacturing Research Services, Inc. v. FDA"
Results 21 - 40
of 56
Sort by Relevance
|
Sort by Date
3 Jan 2012, 10:20 am
Let’s roll the tape. #1: PLIVA, Inc. v. [read post]
27 Dec 2011, 9:56 am
Janssen Pharmaceuticals, Inc., 951 N.E.2d 1238 (Ill. [read post]
11 Nov 2011, 11:55 am
Connex-Metalna Management Consulting GmbH, 302 F.3d 358, 365 (5th Cir. 2002) (quoting United Parcel Service, Inc. v. [read post]
1 Sep 2011, 12:57 pm
IMS Health Inc., 131 S. [read post]
15 Apr 2011, 6:02 am
Mylan Pharmaceuticals, Inc., 2009 WL 7115134, at *2 (N.D. [read post]
22 Mar 2011, 10:57 am
In particular the Court reiterated its prior statement of the standard for materiality in the Basic, Inc. v. [read post]
18 Mar 2010, 2:47 pm
See also Tellabs, Inc. v. [read post]
27 Feb 2009, 5:00 am
(Patent Baristas) US: Teva releases second video in year of affordable healthcare campaign (SmartBrief) US: Discussion of NYT article ‘Crop Scientists Say Biotechnology Seed Companies are Thwarting Research’ (Patent Docs) (Patent Baristas) US FDA: Genetically engineered organisms can be patented (RelatIP) US: Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo seeks review and correction of patent term adjustment for patent covering ‘embolic… [read post]
22 Jan 2009, 2:06 am
Wyeth, Inc., 168 Cal. [read post]
19 Sep 2008, 6:00 pm
: (IP finance), United States: An open letter for the General Counsel of the PTO on your San Diego presentation next week: (Hal Wegner), United States: Cocoa genome: breaking intellectual property barriers: (Thomson Reuters Scientific), Vietnam: Patentability of second medical use claims in Vietnam is again questionable: (Trung Truc JSC) Pharma & Biotech - Products Allegra (Fexofenadine) - Canada: Motion for summary judgment of noninfringement dismissed in patent infringement… [read post]
12 Sep 2008, 2:33 pm
: (IP finance), MARQUES international advertising portal goes live: (Class 46) Global - Patents Using patent landscaping analytics to improve the quality of M & A decisions: a review of Cox Enterprises’ $300M purchase of Adify: (IP Asset Maximiser Blog), Universities reap royalty rewards; investors ignore IP at their peril: (IAM), Top IP-owning nations claim faster patent processing; near harmonisation deal: (Intellectual Property Watch), Bosch, Xerox and Dupont sign up… [read post]
23 Aug 2008, 1:23 am
: (Part 1 - SPICY IP), (Part 2 - SPICY IP) Global – Copyright International Federation of the Phonographic Industry (IFPI): ‘Three strikes’ effort hit worldwide home run: (Ars Technica), How to attribute a Creative Commons licensed work: (Molly Kleinman), Chrysalis disappoints, as new artists fail to incubate: (IP finance), DRM for streaming music dies a quiet death: (Electronic Frontier Foundation), (Techdirt) Events 26 August:… [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
31 Jul 2008, 5:30 pm
Because a manufacturer cannot be required to warn of a risk unknown to science, the knowledge chargeable to him must be limited to that of the period during which the plaintiff was using the product in question.Ortho Pharmaceutical Corp. v. [read post]
24 Jul 2008, 10:00 pm
The Pharmaceutical Research and Manufacturers of America ("PhRMA") released a new set of voluntary guidelines for the conduct of pharmaceutical marketing (called "Code on Interactions with Health Care Professionals") on July 11.That's almost two weeks ago - an eternity in the blogosphere.What can we say? [read post]
18 Jul 2008, 8:34 am
: (GenericsWeb), Eularis analyses most effective generics defence strategies with new pharmaceutical industry report: (GenericsWeb), WIPO symposium to discuss life sciences multilateral environmental agreements: (Daily Dose of IP), Daiichi Sankyo and Ranbaxy confirm deal is binding and final, allay market rumour and speculation: (SmartBrief), Daiichi Ranbaxy takeover and the implications for the future of IP: (Spicy IP), Europe: Cancer Research Therapeutics’ RNAi patent… [read post]
5 Jul 2008, 11:05 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech… [read post]
27 Jun 2008, 10:04 am
: (The Invent Blog), Impressive work on history of ‘Happy Birthday’ and copyright protection: (Innovationpartners), Gender and copyright: (Patry Copyright Blog) Events 1 July: US PLI: ‘Prior art & obviousness 2008: The PTO and CAFC perspective on patent law sections 102 & 103’ - New York: (Patent Docs), 1-2 July – C5 conference on intellectual asset management for high-tech industries – Paris: (c5-online.com), 2… [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO:… [read post]
